SLC6A3 and Tremor: The US Food and Drug Administration has approved molecular dopamine transport (DAT) neuroimaging as an adjunct diagnostic evaluation to help differentiate essential tremor from tremor due to parkinsonian syndromes, whereas the European Medicines Agency (EMA) approved DAT imaging to detect loss of functional dopaminergic neuron terminals in the striatum.2, 3 The role of DAT imaging as a drug‐development tool (DDT) to optimize predictions of motor progression was recognized as having potential as an enrichment biomarker for clinical trials.